Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections

Pharmacotherapy

Volumn 35, Issue 10, 2015, Pages 935-948

  Roberts, Karrine D ^a   Sulaiman, Rand M ^b   Rybak, Michael J ^a,b,c  

^a DETROIT MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dalbavancin; gram positive; infection; lipoglycopeptide; oritavancin; resistance

Indexed keywords

DALBAVANCIN; DAPTOMYCIN; DEXTROMETHORPHAN; LINEZOLID; MIDAZOLAM; OMEPRAZOLE; ORITAVANCIN; RIFAMPICIN; VANCOMYCIN; WARFARIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE; TEICOPLANIN;

ANEMIA; ANTHRAX; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CATHETER INFECTION; CELLULITIS; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; ENTEROCOCCAL INFECTION; ERYSIPELAS; FLUSHING; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; INFUSION RELATED REACTION; INJECTION SITE EXTRAVASATION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OSTEOMYELITIS; PARTIAL THROMBOPLASTIN TIME; PHLEBITIS; PLASMA HALF LIFE; PNEUMOCOCCAL MENINGITIS; PRURITUS; RASH; SINGLE DRUG DOSE; SKIN ABSCESS; STAPHYLOCOCCUS INFECTION; URTICARIA; VOMITING; WOUND INFECTION; ANALOGS AND DERIVATIVES; ANIMAL; CROSS INFECTION; DRUG INTERACTION; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF LIFE TIME; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASES, BACTERIAL; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG INTERACTIONS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; TEICOPLANIN; UNITED STATES; VANCOMYCIN RESISTANCE;

EID: 84945130055     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1641     Document Type: Article

References (61)

1. Sievert DM, Ricks P, Edwards JR, et al., Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34 (1): 1-14.
2. Dryden MS,. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 (Suppl 3): iii35-44.
3. Stryjewski ME, Chambers HF,. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 (Suppl 5): S368-77.
4. Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J,. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr Med Res Opin 2008; 24 (10): 2821-8.
5. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC,. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40 (1): 135-6.
6. Jones RN,. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 (Suppl 1): S13-24.
7. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN,. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46 (9): 2950-4.
8. Arthur M, Depardieu F, Reynolds P, Courvalin P,. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999; 43 (8): 1875-80.
9. Munch D, Engels I, Muller A, et al., Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother 2015; 59 (2): 772-81.
10. Cheng M, Ziora ZM, Hansford KA, Blaskovich MA, Butler MS, Cooper MA,. Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin. Org Biomol Chem 2014; 12 (16): 2568-75.
11. Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF,. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007; 51 (4): 1150-4.
12. Buckwalter M, Dowell JA,. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005; 45 (11): 1279-87.
13. Cavaleri M, Riva S, Valagussa A, et al., Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005; 55 (Suppl 2): ii31-5.
14. Leighton A, Gottlieb AB, Dorr MB, et al., Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48 (3): 940-5.
15. McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW,. In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program. Antimicrob Agents Chemother 2015; 59 (8): 5007-9.
16. Jones RN, Sader HS, Flamm RK,. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013; 75 (3): 304-7.
17. Citron DM, Tyrrell KL, Goldstein EJ,. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis 2014; 79 (4): 438-40.
18. Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance A. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69 (3): 342-7.
19. CLSI. Performance standards for antimicrobial susceptibility tests for bacteria that aerobically. Approved Standard, 10th ed. Wayne, PA: CLSI; 2012.
20. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN,. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother 2014; 58 (5): 2921-4.
21. Vidaillac C, Parra-Ruiz J, Rybak MJ,. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn Microbiol Infect Dis 2011; 71 (4): 470-3.
22. Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF,. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother 2009; 53 (11): 4762-71.
23. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN,. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009; 53 (3): 1260-3.
24. Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN,. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol 2007; 45 (3): 998-1004.
25. Gales AC, Sader HS, Jones RN,. Antimicrobial activity of dalbavancin tested against gram-positive clinical isolates from Latin American Medical Centres. Clin Microbiol Infect 2005; 11 (2): 95-100.
26. Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP,. Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006; 54 (2): 149-53.
27. Bozdogan B, Ednie L, Credito K, Kosowska K, Appelbaum PC,. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004; 48 (12): 4762-5.
28. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC,. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52 (5): 864-8.
29. Lin G, Credito K, Ednie LM, Appelbaum PC,. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49 (2): 770-2.
30. Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA,. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007; 60 (3): 681-4.
31. Andes D, Craig WA,. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51 (5): 1633-42.
32. Baldoni D, Furustrand Tafin U, Aeppli S, et al., Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Int J Antimicrob Agents 2013; 42 (3): 220-5.
33. Darouiche RO, Mansouri MD,. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect 2005; 50 (3): 206-9.
34. Raad I, Darouiche R, Vazquez J, et al., Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40 (3): 374-80.
35. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW,. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370 (23): 2169-79.
36. Durata. Dalvance (dalbavancin) for injection [package insert]. Chicago, IL; 2014.
37. Marbury T, Dowell JA, Seltzer E, Buckwalter M,. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009; 49 (4): 465-76.
38. Jauregui LE, Babazadeh S, Seltzer E, et al., Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41 (10): 1407-15.
39. Allen NE, Nicas TI,. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003; 26 (5): 511-32.
40. Kim SJ, Cegelski L, Stueber D, et al., Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008; 377 (1): 281-93.
41. Patti GJ, Kim SJ, Yu TY, et al., Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol 2009; 392 (5): 1178-91.
42. Kim SJ, Cegelski L, Preobrazhenskaya M, Schaefer J,. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance. Biochemistry 2006; 45 (16): 5235-50.
43. Kim SJ, Cegelski L, Studelska DR, O'Connor RD, Mehta AK, Schaefer J,. Rotational-echo double resonance characterization of vancomycin binding sites in Staphylococcus aureus. Biochemistry 2002; 41 (22): 6967-77.
44. Belley A, Neesham-Grenon E, McKay G, et al., Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009; 53 (3): 918-25.
45. McKay GA, Beaulieu S, Arhin FF, et al., Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009; 63 (6): 1191-9.
46. Arhin FF, Sarmiento I, Parr TR Jr, Moeck G,. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009; 64 (4): 868-70.
47. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG,. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004; 50 (2): 95-102.
48. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A,. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009; 53 (10): 4422-8.
49. Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G,. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2013; 57 (1): 205-11.
50. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr,. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003; 47 (5): 1700-6.
51. Gerber J, Smirnov A, Wellmer A, et al., Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001; 45 (7): 2169-72.
52. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ,. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42 (4): 981-3.
53. Rupp ME, Fey PD, Longo GM,. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother 2001; 47 (5): 705-7.
54. Heine HS, Bassett J, Miller L, et al., Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother 2008; 52 (9): 3350-7.
55. Lehoux D, Ostiguy V, Fadhil L, et al., Efficacy of oritavancin (ORI) in the mouse bacteremia model [abstract B-1009]. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. Washington, DC: American Society for Microbiology, 2008.
56. Dunbar LM, Milata J, McClure T, Wasilewski MM, Team SS,. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011; 55 (7): 3476-84.
57. Corey GR, Good S, Jiang H, et al., Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II Noninferiority Study. Clin Infect Dis 2015; 60 (2): 254-62.
58. Corey GR, Kabler H, Mehra P, et al., Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370 (23): 2180-90.
59. Medicines Company. Orbactiv (oritavancin) for injection [package insert]. Parsippany, NJ; 2014.
60. Ambrose PG, Drusano GL, Craig WA,. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012; 54 (Suppl 3): S220-8.
61. Greenblatt DJ, Zhao Y, Duan SX, et al., Effect of oritavancin on human cytochrome P450 in vitro [poster no. A1-1284]. 49th Interscience Conferene on Antimicrobial Agents and Chemotherapy; September 12-15; San Francisco, CA; 2009.